Site for AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
Site for This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. CPX-351 is made up of daunorubicin and cytarabine and is made in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drug. Some acute myeloid leukemia patients have an abnormality in the structure of a gene called FLT3. Genes are pieces of DNA (molecules that carry instructions for development, functioning, growth and reproduction) inside each cell that tell the cell what to do and when to grow and divide. FLT3 plays an important role in the normal making of blood cells. This gene can have permanent changes that cause it to function abnormally by making cancer cells grow. Gilteritinib may block the abnormal function of the FLT3 gene that makes cancer cells grow. The overall goals of this study are, 1) to compare the effects, good and/or bad, of CPX-351 with daunorubicin and cytarabine on people with newly diagnosed AML to find out which is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function during and after treatment for AML. Giving CPX-351 and/or gilteritinib with standard chemotherapy may work better in treating patients with acute myeloid leukemia compared to standard chemotherapy alone.
Site for Abaloparatide versus Placebo for Pelvic Fracture Healing - A Phase 2 Randomized Controlled Trial
Site for This is a prospective randomized, double-blinded, placebo-controlled, phase 2, three-month study of the efficacy of abaloparatide in postmenopausal women and men = 50 years of age with acute fractures of the pelvis. We will extend this study with 9 months of open label abaloparatide to determine if any potential differences between the placebo and abaloparatide groups during the 3 months of treatment are evident and persist over time, even in patients who use abaloparatide after the three-month placebo controlled intervention.Our primary outcome is CT evidence of fracture healing at the 12-week endpoint. After initiating ABALOPARATIDE or ABALOPARATIDE placebo, all patients will get follow-up pelvic radiographs following standard care and radiographs will stop when healing occurs.
Site for AN INTERVENTIONAL MULTI-CENTER INVESTIGATION OF SINGLE LEVEL TRANSFORAMINAL LUMBAR INTERBODY FUSION (TLIF) STABILIZED WITH PEDICLE SCREWS
Site for An interventional, multi-center (up to 15), prospective, non-blinded investigation of single-level TLIF stabilized with pedicle screws. The purpose is to intend to treat the study population by demonstrating clinical success (safety and efficacy) of the TLIF instrumented with pedicle screws with respect to composite endpoints.
Site for I4V-MC-JAJD - A Randomized Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
Site for Study I4V-MC-JAJD (JAJD) is a Phase 3b/4, multicenter, randomized, parallel-group,active-controlled, pragmatic, event-driven study to evaluate the effects of baricitinib (2 mg and 4 mg daily) compared with tumor necrosis factor (TNF) inhibitors (administered according to approved local labeling) on risk of VTE and other key safety endpoints in patients with RA receiving routine clinical care. Consistent with the pragmatic intent of this study, once randomized, treatment will be provided through mechanisms available to patients in routine care and will be open-label for patients and study-site personnel.
Site for Intermediate Patient Population Expanded Access Protocol for MBP134 for Participants with Sudan Virus Disease (SVD)
The goal of this study is to see if a drug called MBP134 works to help patients get better from Sudan Virus Disease (SVD).
Site for Mechanistic registry to examine whether the corona virus disease 2019 (COVID-19) accelerates atherosclerotic plaque progression
The purpose of this study is to determine if coronary disease patientswith a history of COVID-19 infection have more inflammation, resultingin faster development of plaque in their coronary arteries whencompared to patients with no prior history of COVID-19 infection.
Site for PNOC027; A pilot trial of real time drug screening and genomic testing to determine an individualized treatment plan in children and young adults with relapsed medulloblastoma
Site for The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility of performing real-time drug screening on tissue taken during surgery, and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with medulloblastoma to receive the most effective and least toxic therapies currently available, and will pave the way for improved understanding and treatment of these tumors in the future.
Site for Registry of Asthma Patients Initiating
Site for Participant in this observational research study sponsored by Regeneron Pharmaceuticals, Inc., are being asked to participate because they are receiving treatment with dupilumab, since you are currently being treated for asthma by a study participating physician. The study is being done to characterize and collect long term data on patients 12 years and older with moderate to severe asthma, who receive treatment with dupilumab (also known as DUPIXENT®).
Site for Studies of Patients with Implanted Intracranial Electrodes
Site for The overall goals of this research protocol are 1) to better understand the function of cortical sites that are measured with scalp electrodes (electroencephalography, or EEG) and/or implanted intracranial electrodes (electrocorticography, or ECoG) and 2) to determine the most effective and safe testing methods, including cortical stimulation and passive EEG or ECoG recordings, for defining this cortical function so that post-operative neurological impairments are avoided.
Site for Understanding health disparities in Pakistani Bangladeshi and Asian Indian immigrants: the role of socio-cultural context acculturation and resilience resources - Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study Expansion New York Site
Site for This protocol describes a mixed methods study that leverages the infrastructure of an ongoing MASALA study in Chicago and San Francisco to enroll 600 Bangladeshi and 250 Pakistani adults aged 40-84 years as part of a greater New York City cohort. These participants will be added to the 1,550 surviving participants already in MASALA for well-powered subgroup comparisons and ongoing follow-up. Participants will complete a physical exam and survey, provide biospecimens, and be followed longitudinally (12M, 24M) to complete surveys in order to identify how socio-cultural context, discrimination, acculturation strategies and resilience resources act as risk or protective factors explaining CVH disparities in Indian, Pakistani and Bangladeshi immigrants.